News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,986 Results
Type
Article (14181)
Company Profile (258)
Press Release (247547)
Section
Business (80657)
Career Advice (213)
Deals (13539)
Drug Delivery (28)
Drug Development (50511)
Employer Resources (33)
FDA (5704)
Job Trends (5227)
News (146024)
Policy (10385)
Tag
Academia (964)
Africa (165)
Allergies (30)
Alliances (21902)
Alzheimer's disease (703)
Antibody-drug conjugate (ADC) (31)
Approvals (5666)
Arizona (38)
Artificial intelligence (36)
Asia (16822)
Australia (2831)
Bankruptcy (100)
Best Places to Work (4447)
Biotechnology (216)
C2C Services and Suppliers (11308)
California (1213)
Canada (493)
Cancer (292)
Career advice (181)
CAR-T (34)
Cell therapy (95)
China (88)
Clinical research (39257)
Collaboration (85)
Colorado (35)
Compensation (39)
Connecticut (40)
COVID-19 (1013)
Cystic fibrosis (58)
Data (215)
Diabetes (39)
Diagnostics (1305)
Earnings (28920)
Employer resources (31)
Europe (36766)
Events (46448)
Executive appointments (95)
FDA (5817)
Florida (120)
Funding (97)
Gene editing (28)
Gene therapy (79)
GLP-1 (269)
Government (1167)
Healthcare (6762)
Hotbed/Location (187820)
Illinois (77)
Indiana (46)
Infectious disease (1022)
Inflammatory bowel disease (81)
IPO (7296)
Job creations (876)
Job search strategy (165)
Kansas (55)
Layoffs (178)
Legal (1431)
Lung cancer (69)
Maryland (189)
Massachusetts (988)
Medical device (2676)
Medtech (2677)
Mergers & acquisitions (6239)
Metabolic disorders (131)
Michigan (37)
Minnesota (66)
Neuroscience (807)
New Jersey (331)
New York (390)
NextGen Class of 2024 (2040)
Non-profit (909)
North Carolina (328)
Northern California (533)
Obesity (75)
Ohio (64)
Opinion (92)
Parkinson's disease (31)
Patents (35)
Pennsylvania (276)
People (25015)
Pharmaceutical (41)
Phase I (13751)
Phase II (18265)
Phase III (11630)
Pipeline (72)
Postmarket research (862)
Preclinical (5791)
Press Release (30)
Rare diseases (102)
Real estate (1440)
Regulatory (8224)
Research institute (962)
Resumes & cover letters (31)
South America (220)
Southern California (509)
Startups (1990)
Texas (113)
United States (4660)
Vaccines (135)
Washington State (153)
Weight loss (59)
Date
Today (62)
Last 7 days (413)
Last 30 days (1358)
Last 365 days (21897)
2024 (15249)
2023 (22799)
2022 (27289)
2021 (28413)
2020 (24007)
2019 (16836)
2018 (12188)
2017 (14070)
2016 (12171)
2015 (14702)
2014 (10594)
2013 (7646)
2012 (7685)
2011 (7793)
2010 (7547)
261,986 Results for "context therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights.
May 8, 2024
·
6 min read
Pharm Country
Context Therapeutics Announces $100 Million Private Placement
Context Therapeutics Inc. today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds of approximately $100.0 million, before deducting placement agent fees and estimated offering expenses.
May 2, 2024
·
5 min read
Business
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Context Therapeutics Inc. today announced its financial results for the year ended December 31, 2023.
March 21, 2024
·
7 min read
Press Releases
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
September 5, 2024
·
5 min read
Drug Development
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody.
May 2, 2024
·
4 min read
Business
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
August 7, 2024
·
6 min read
Drug Development
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Context Therapeutics Inc. Today announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76.
April 1, 2024
·
4 min read
Press Releases
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
August 1, 2024
·
6 min read
News
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
July 10, 2024
·
4 min read
Business
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights.
November 9, 2023
·
6 min read
1 of 26,199
Next
